Aurobindo Pharma Q3 FY26: Consol revenue up 8%, standalone PAT jumps 23%
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts less than Nifty Midcap 150 and 6.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aurobindo Pharma Q3 FY26: Standalone net sales fell 5.4% YoY to Rs 27,264M but PAT rose 23.3% to Rs 5,821M on lower costs and higher other income. Standalone 9M PAT up 28.7% at Rs 17,226M. Consolidated Q3 revenue up 8.4% to Rs 86,459M, PAT up 7.6% at Rs 9,098M. 9M consol PAT nearly flat at Rs 25,821M. Exceptional charge of Rs 653M (consol) on Labour Codes. Agreed to acquire Lannett Company and Khandelwal Labs non-oncology business for Rs 3,250M. Auditor issued unmodified review.
Margin expansion offsets standalone revenue softness; acquisitions and new subsidiaries add growth optionality. Watch margin sustainability.